Point72 Asset Management L.P. purchased a new stake in shares of Kura Oncology Inc (NASDAQ:KURA) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 132,546 shares of the company’s stock, valued at approximately $2,412,000. Point72 Asset Management L.P. owned about 0.35% of Kura Oncology at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bank of America Corp DE grew its stake in shares of Kura Oncology by 327.1% during the second quarter. Bank of America Corp DE now owns 17,729 shares of the company’s stock valued at $323,000 after purchasing an additional 13,578 shares during the last quarter. Prosight Management LP acquired a new position in Kura Oncology in the second quarter valued at approximately $5,240,000. Voya Investment Management LLC acquired a new position in Kura Oncology in the second quarter valued at approximately $187,000. BB&T Securities LLC acquired a new position in Kura Oncology in the second quarter valued at approximately $291,000. Finally, DAFNA Capital Management LLC lifted its holdings in Kura Oncology by 88.6% in the second quarter. DAFNA Capital Management LLC now owns 239,500 shares of the company’s stock valued at $4,359,000 after buying an additional 112,500 shares during the period. 77.28% of the stock is currently owned by institutional investors and hedge funds.
KURA traded up $0.20 during mid-day trading on Friday, hitting $15.66. The stock had a trading volume of 191,827 shares, compared to its average volume of 286,365. The company has a debt-to-equity ratio of 0.04, a quick ratio of 10.22 and a current ratio of 10.22. The firm has a market cap of $664.57 million, a PE ratio of -10.30 and a beta of 4.20. Kura Oncology Inc has a 1-year low of $12.10 and a 1-year high of $24.02.
Kura Oncology (NASDAQ:KURA) last posted its earnings results on Thursday, August 9th. The company reported ($0.45) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.45). Equities analysts forecast that Kura Oncology Inc will post -1.73 EPS for the current fiscal year.
Several equities analysts recently weighed in on KURA shares. BidaskClub upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a report on Tuesday, June 19th. ValuEngine upgraded shares of Kura Oncology from a “buy” rating to a “strong-buy” rating in a report on Monday, July 2nd. Oppenheimer increased their price objective on shares of Kura Oncology from $27.00 to $35.00 and gave the company an “outperform” rating in a report on Monday, July 9th. Finally, HC Wainwright started coverage on shares of Kura Oncology in a report on Wednesday, August 1st. They issued a “buy” rating and a $31.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating to the company. Kura Oncology has an average rating of “Buy” and a consensus price target of $27.00.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Featured Article: Terms to Better Understand Call Options
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.